Spots Global Cancer Trial Database for Predictive Proteomic Factors of the Response to Concomitant Radiochemotherapy in Esophageal Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Predictive Proteomic Factors of the Response to Concomitant Radiochemotherapy in Esophageal Cancer
Official Title: Study of Predictive Proteomic Factors of the Response to Exclusive Concomitant Radiochemotherapy in Oesophageal Cancer
Study ID: NCT00911092
Conditions
Study Description
Brief Summary: The scope of the trial is to predict the early complete clinical response to exclusive concomitant radiochemotherapy in esophageal cancer by the study of the pre- and per- therapeutic proteomic profile.
Detailed Description: Further informations will be provided by Centre Oscar Lambret.
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Centre Paul Papin, Angers, , France
Centre Hospitalier Universitaire, Brest, , France
Centre François BACLESSE, Caen, , France
Centre Oscar Lambret, Lille, , France
Centre Eugène Marquis, Rennes, , France
CHU - Hopital Charles Nicolle, Rouen, , France
Contact Details
Name: ADENIS Antoine, MD, PhD
Affiliation: Centre Oscar Lambret
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
